

72/LG/SE/APRIL/2020/GBSL

**April 24, 2020**

To  
The Manager (CRD)  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai – 400 001

**Scrip Code : 509079**

To  
The Manager  
**National Stock Exchange Of India Limited**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Symbol : GUFICBIO**

Dear Sirs,

**Sub: Intimation under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015**

This is in reference with the Scheme of Amalgamation of Gufic Biosciences Limited ('the Company') with Gufic Lifesciences Private Limited ("GLPL") and their respective shareholders and creditors, for which "Observation Letters" with no adverse remarks have been received by BSE Limited and National Stock Exchange of India Limited vide their letters dated April 15, 2020.

We are pleased to inform you that GLPL have been approved by ANVISA, Brazil and with this approval, GLPL can now expand its business in the territory of Brazil.

*ANVISA is an autarchy linked to the Ministry of Health, part of the Brazilian National Health System as the coordinator of the Brazilian Health Regulatory System (SNVS). ANVISA's role is to promote the protection of the health of the Brazilian population by executing sanitary control of the production, marketing and use of products and services subject to health regulation, including related environments, processes, ingredients and technologies, as well as the control in ports, airports and borders. (Source: <http://portal.anvisa.gov.br/english>).*

The brief information about Brazilian market and the benefit that shall be accrued by getting ANVISA certification by GLPL, is enclosed herewith, for your reference.

Further, the Company is in process of approaching Hon'ble National Company Law Tribunal for further process of amalgamation. Post amalgamation, the Company will enjoy the benefits as stated hereinabove.

Kindly take the same on record.

Yours faithfully,

**For Gufic Biosciences Limited**



**Ami Shah**  
**Company Secretary**  
**Membership No. A39579**

**Encl: A/a**

## **Gufic Lifesciences Private Limited - Gets ANVISA, Brazil Approval for its Injectable plant**

*The development opens up the 6<sup>th</sup> Largest Global Pharmaceutical market for GLPL*

GLPL announced the approval of its Lyophilized injectable plant at Navsari, Gujarat by the Brazilian regulatory body - ANVISA.

This opens up the 6<sup>th</sup> largest Global market in value terms for the company that has clocked the highest growth amongst the top 100 companies in India.

The improving economy in Brazil, supported by market-oriented reforms, is expected to boost growth in the pharmaceuticals market in the short-to-medium term.

Currently the Brazilian market is valued at USD 27 Billion and shows a growth of 8 % and a unit growth of around 10 %. It is forecasted that the Brazilian market would touch a figure of USD 48 Billion by 2023.

The Non-retail segment which includes primarily the injectable shows a very healthy growth of 18 %

Strong demographics, rising employment levels, higher disposable incomes and encouraging generic medicines sales in Brazil are major drivers for the pharmaceutical market over the 2019-2023 period.

GLPL is currently in talks with several partners to explore potential partnerships to enter into this futuristic market. GLPL is also in the process of gearing-up its manufacturing capabilities to cater to the needs of multiple countries since it now has regulatory approvals of more than 20 countries including the EU GMP.